Blogs

Latest Blogs

The Silence of the Genes: Unlocking Antisense Oligonucleotide Therapies for the Renin-Angiotensin-Aldosterone System

October 22, 2025

The field of gene therapy is rapidly evolving, with antisense oligonucleotide therapies emerging as powerful tools for modulating gene expression.…

From Signals to Systems: Olink Proteomics as a Cornerstone of Synexa’s Biomarker Strategy

October 14, 2025

We have entered a new era of modern science, where therapeutic innovation is reshaping the field of medicine.…

GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions

September 11, 2025

Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…

Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial

July 2, 2025

We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…

From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS

June 18, 2025

Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…

Establishing Biosimilarity: Regulatory and Scientific Expectations

June 5, 2025

A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…

Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures

May 15, 2025

We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…